Core Viewpoint - A securities fraud class action lawsuit has been filed against Edwards Lifesciences Corporation, alleging misrepresentations related to its Transcatheter Aortic Valve Replacement platform and market demand [2]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Central District of California on behalf of investors who purchased Edwards securities between February 6, 2024, and July 24, 2024 [2]. - Allegations include violations of the Securities Exchange Act of 1934, with claims that Edwards misrepresented its commitment to the Transcatheter Aortic Valve Replacement platform and its ability to engage untreated patients [2]. Group 2: Legal Representation and Actions - Investors wishing to serve as lead plaintiffs must file necessary documents by December 13, 2024, although participation as a class member does not require this [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [3].

Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that Edwards Lifesciences misrepresented the demand and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) platform, claiming that the company failed to reach the low-treatment-rate population and that healthcare organizations prioritized other treatments [2]. - On July 24, 2024, Edwards Lifesciences reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for TAVR in fiscal Q2 2024, leading to a 31% decline in stock price from $86.95 to $59.70 per share [3]. Group 2: Company Background - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, categorizing its products into four main areas: TAVR, Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart therapies, and Critical Care therapies [2].

SAN DIEGO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charg ...

Group 1 - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] - The lawsuit alleges that Edwards Lifesciences misrepresented the demand and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) platform, claiming that patient activation activities were ineffective and that healthcare organizations prioritized other treatments [2][3] - Following a significant reduction in TAVR guidance and disappointing financial results announced on July 24, 2024, Edwards' stock price dropped by 31%, from $86.95 to $59.70 per share [3] Group 2 - Investors in Edwards Lifesciences are encouraged to seek legal options and submit their information to the law firm representing the case, with no upfront costs for shareholders [4] - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and has achieved notable recoveries in past cases, including over $900 million from Tesla, Inc. [4]

RADNOR, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is Dece ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 13, 2024. So what: If you purchased Edwards Lifesciences Corporation se ...

Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims related to misleading statements about the company's TAVR platform and its market demand [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation, et al., No. 24-cv-02221 [2]. - Investors have until December 13, 2024, to request to lead the case [2]. Group 2: Company Overview - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, as well as critical care monitoring solutions, categorized into four main therapy types: TAVR, TMTT, Surgical Structural Heart therapies, and Critical Care therapies [3]. Group 3: Allegations and Impact - The complaint alleges that Edwards misrepresented the demand for its TAVR platform, claiming significant unmet demand while the actual growth had stalled due to ineffective patient activation activities and prioritization of other treatments by healthcare organizations [4]. - On July 24, 2024, Edwards reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for the second quarter, leading to a 31% decline in stock price from $86.95 to $59.70 per share [5][6].

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=108710&from=4 CLASS PERIOD: F ...

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 6, 2024 – July 24, 2024 Lead Plaintiff Deadline: Dec. 13, 2024 Visit: www.hbsslaw.com/investor-fraud/ew Contact the Firm Now: EW@hbsslaw.com 844-916-0895 Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences' disclosures about its ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's in ...